• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

空间免疫表型可预测肝内胆管癌的临床结局。

Spatial immunophenotypes predict clinical outcome in intrahepatic cholangiocarcinoma.

作者信息

Zhu Chunbin, Ma Jiaqiang, Zhu Kai, Yu Lei, Zheng Bohao, Rao Dongning, Zhang Shu, Dong Liangqing, Gao Qiang, Zhang Xiaoming, Xie Diyang

机构信息

Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Fudan University, Shanghai, 200032, China.

The Center for Microbes, Development and Health, Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China.

出版信息

JHEP Rep. 2023 Apr 15;5(8):100762. doi: 10.1016/j.jhepr.2023.100762. eCollection 2023 Aug.

DOI:10.1016/j.jhepr.2023.100762
PMID:37360908
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10285646/
Abstract

BACKGROUND & AIMS: Intrahepatic cholangiocarcinoma (iCCA) is a severe malignant tumour that shows only modest responses to immunotherapy. We aimed to identify the spatial immunophenotypes of iCCA and delineate potential immune escape mechanisms.

METHOD

Multiplex immunohistochemistry (mIHC) was performed to quantitatively evaluate the distribution of 16 immune cell subsets in intratumour, invasive margin and peritumour areas in a cohort of 192 treatment-naïve patients with iCCA. Multiregion unsupervised clustering was used to determine three spatial immunophenotypes, and multiomics analyses were carried out to explore functional differences.: iCCA displayed a region-specific distribution of immune cell subsets with abundant CD15 neutrophil infiltration in intratumour areas. Three spatial immunophenotypes encompassing inflamed (35%), excluded (35%) and ignored (30%) phenotypes were identified. The inflamed phenotype showed characteristics of abundant immune cell infiltration in intratumour areas, increased PD-L1 expression and relatively favourable overall survival. The excluded phenotype with a moderate prognosis was characterized by immune cell infiltration restricted to the invasive margin or peritumour areas and upregulation of activated hepatic stellate cells, extracellular matrix and Notch signalling pathways. The ignored phenotype, with scarce immune cell infiltration across all subregions, was associated with MAPK signalling pathway elevation and a poor prognosis. The excluded and ignored phenotypes, constituting non-inflamed phenotypes, shared features of an increased angiogenesis score, TGF-β and Wnt-β catenin pathway upregulation and were enriched for mutations and fusions.

CONCLUSION

We identified three spatial immunophenotypes with different overall prognoses in iCCA. Tailored therapies based on the distinct immune evasion mechanisms of the spatial immunophenotypes are needed.

IMPACT AND IMPLICATIONS

The contribution of immune cell infiltration in the invasive margin and peritumour areas has been proved. We explored the multiregional immune contexture of 192 patients to identify three spatial immunophenotypes in intrahepatic cholangiocarcinoma (iCCA). By integrating genomic and transcriptomic data, phenotype-specific biological behaviours and potential immune escape mechanisms were analysed. Our findings provide a rationale to develop personalized therapies for iCCA.

摘要

背景与目的

肝内胆管癌(iCCA)是一种严重的恶性肿瘤,对免疫疗法的反应有限。我们旨在确定iCCA的空间免疫表型,并描述潜在的免疫逃逸机制。

方法

对192例未经治疗的iCCA患者队列进行多重免疫组化(mIHC),以定量评估肿瘤内、浸润边缘和瘤周区域16种免疫细胞亚群的分布。采用多区域无监督聚类确定三种空间免疫表型,并进行多组学分析以探索功能差异。iCCA显示免疫细胞亚群的区域特异性分布,肿瘤内区域有丰富的CD15中性粒细胞浸润。确定了三种空间免疫表型,包括炎症型(35%)、排除型(35%)和忽略型(30%)。炎症型在肿瘤内区域表现为丰富的免疫细胞浸润、PD-L1表达增加和相对较好的总生存期。排除型预后中等,其特征是免疫细胞浸润局限于浸润边缘或瘤周区域,以及活化肝星状细胞、细胞外基质和Notch信号通路的上调。忽略型在所有亚区域免疫细胞浸润稀少,与MAPK信号通路升高和预后不良相关。排除型和忽略型构成非炎症型,具有血管生成评分增加、TGF-β和Wnt-β连环蛋白通路上调的共同特征,并且富集了 突变和 融合。

结论

我们在iCCA中确定了三种总体预后不同的空间免疫表型。需要基于空间免疫表型独特的免疫逃逸机制进行针对性治疗。

影响与意义

已证实免疫细胞浸润在浸润边缘和瘤周区域的作用。我们研究了192例患者的多区域免疫背景,以确定肝内胆管癌(iCCA)的三种空间免疫表型。通过整合基因组和转录组数据,分析了表型特异性的生物学行为和潜在的免疫逃逸机制。我们的研究结果为开发iCCA的个性化治疗提供了理论依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9741/10285646/195ff379ef52/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9741/10285646/195ff379ef52/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9741/10285646/195ff379ef52/ga1.jpg

相似文献

1
Spatial immunophenotypes predict clinical outcome in intrahepatic cholangiocarcinoma.空间免疫表型可预测肝内胆管癌的临床结局。
JHEP Rep. 2023 Apr 15;5(8):100762. doi: 10.1016/j.jhepr.2023.100762. eCollection 2023 Aug.
2
Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma.三级淋巴结构的分布和密度可预测肝内胆管癌的临床结局。
J Hepatol. 2022 Mar;76(3):608-618. doi: 10.1016/j.jhep.2021.10.030. Epub 2021 Nov 15.
3
Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.基于新型微环境的肝内胆管癌分类及其治疗意义。
Gut. 2023 Apr;72(4):736-748. doi: 10.1136/gutjnl-2021-326514. Epub 2022 May 18.
4
Geospatial Immune Heterogeneity Reflects the Diverse Tumor-Immune Interactions in Intrahepatic Cholangiocarcinoma.空间免疫异质性反映了肝内胆管癌中不同的肿瘤免疫相互作用。
Cancer Discov. 2022 Oct 5;12(10):2350-2371. doi: 10.1158/2159-8290.CD-21-1640.
5
FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma.成纤维细胞生长因子受体 2 融合蛋白促使小鼠肝类器官向胆管癌的致癌转化。
J Hepatol. 2021 Aug;75(2):351-362. doi: 10.1016/j.jhep.2021.02.032. Epub 2021 Mar 17.
6
Multiomics analysis reveals metabolic subtypes and identifies diacylglycerol kinase α (DGKA) as a potential therapeutic target for intrahepatic cholangiocarcinoma.多组学分析揭示代谢亚型并确定二酰甘油激酶α(DGKA)作为肝内胆管癌的潜在治疗靶点。
Cancer Commun (Lond). 2024 Feb;44(2):226-250. doi: 10.1002/cac2.12513. Epub 2023 Dec 24.
7
Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target.肝内胆管癌的多模态单细胞分析将高激活的调节性T细胞定义为潜在治疗靶点。
J Hepatol. 2022 Nov;77(5):1359-1372. doi: 10.1016/j.jhep.2022.05.043. Epub 2022 Jun 20.
8
Systematic profiling of mitochondria-related transcriptome in tumorigenesis, prognosis, and tumor immune microenvironment of intrahepatic cholangiocarcinoma: a multi-center cohort study.肝内胆管癌发生、预后及肿瘤免疫微环境中线粒体相关转录组的系统分析:一项多中心队列研究
Front Genet. 2024 Jul 26;15:1430885. doi: 10.3389/fgene.2024.1430885. eCollection 2024.
9
Genetic/Epigenetic Alteration and Tumor Immune Microenvironment in Intrahepatic Cholangiocarcinoma: Transforming the Immune Microenvironment with Molecular-Targeted Agents.肝内胆管癌中的遗传/表观遗传改变与肿瘤免疫微环境:用分子靶向药物改变免疫微环境
Liver Cancer. 2023 Oct 4;13(2):136-149. doi: 10.1159/000534443. eCollection 2024 Apr.
10
Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma.肝内胆管癌的最新病理分类及分子特征
Front Med (Lausanne). 2022 Mar 31;9:857140. doi: 10.3389/fmed.2022.857140. eCollection 2022.

引用本文的文献

1
Immunotherapy in biliary tract cancer: reshaping the tumour microenvironment and advancing precision combination strategies.胆管癌的免疫治疗:重塑肿瘤微环境与推进精准联合策略
Front Immunol. 2025 Aug 8;16:1651769. doi: 10.3389/fimmu.2025.1651769. eCollection 2025.
2
Prediction of PD-L1 expression and prognosis of mass-forming intrahepatic cholangiocarcinoma based on preoperative magnetic resonance imaging.基于术前磁共振成像预测肿块型肝内胆管癌的PD-L1表达及预后
Quant Imaging Med Surg. 2025 Aug 1;15(8):6822-6837. doi: 10.21037/qims-24-2130. Epub 2025 Jul 30.
3
Single-cell transcription reveals hepatocyte-to-cholangiocyte reprogramming and biliary gene profile in biliary atresia.

本文引用的文献

1
Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilities.多模块分析肝内胆管癌免疫亚群揭示了不同的治疗弱点。
J Immunother Cancer. 2022 Jul;10(7). doi: 10.1136/jitc-2022-004892.
2
Geospatial Immune Heterogeneity Reflects the Diverse Tumor-Immune Interactions in Intrahepatic Cholangiocarcinoma.空间免疫异质性反映了肝内胆管癌中不同的肿瘤免疫相互作用。
Cancer Discov. 2022 Oct 5;12(10):2350-2371. doi: 10.1158/2159-8290.CD-21-1640.
3
Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.
单细胞转录揭示了胆道闭锁中肝细胞向胆管细胞的重编程及胆管基因谱。
Hepatol Commun. 2025 May 6;9(5). doi: 10.1097/HC9.0000000000000710. eCollection 2025 May 1.
4
Biomarkers and Management of Cholangiocarcinoma: Unveiling New Horizons for Precision Therapy.胆管癌的生物标志物与管理:开启精准治疗的新视野
Cancers (Basel). 2025 Apr 6;17(7):1243. doi: 10.3390/cancers17071243.
5
Tumor Immune Microenvironment in Intrahepatic Cholangiocarcinoma: Regulatory Mechanisms, Functions, and Therapeutic Implications.肝内胆管癌的肿瘤免疫微环境:调控机制、功能及治疗意义
Cancers (Basel). 2024 Oct 20;16(20):3542. doi: 10.3390/cancers16203542.
6
Prognostic impact of the tumour microenvironment in intrahepatic cholangiocarcinoma: identification of a peritumoural fibro-immune interface.肿瘤微环境对肝内胆管癌预后的影响:肿瘤周围纤维免疫界面的鉴定。
Virchows Arch. 2024 Nov;485(5):901-911. doi: 10.1007/s00428-024-03922-5. Epub 2024 Sep 6.
7
Unveil Intrahepatic Cholangiocarcinoma Heterogeneity through the Lens of Omics and Multi-Omics Approaches.通过组学和多组学方法揭示肝内胆管癌的异质性
Cancers (Basel). 2024 Aug 20;16(16):2889. doi: 10.3390/cancers16162889.
8
Genetic/Epigenetic Alteration and Tumor Immune Microenvironment in Intrahepatic Cholangiocarcinoma: Transforming the Immune Microenvironment with Molecular-Targeted Agents.肝内胆管癌中的遗传/表观遗传改变与肿瘤免疫微环境:用分子靶向药物改变免疫微环境
Liver Cancer. 2023 Oct 4;13(2):136-149. doi: 10.1159/000534443. eCollection 2024 Apr.
基于新型微环境的肝内胆管癌分类及其治疗意义。
Gut. 2023 Apr;72(4):736-748. doi: 10.1136/gutjnl-2021-326514. Epub 2022 May 18.
4
B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome.B 细胞和三级淋巴结构作为肿瘤免疫微环境和临床结局的决定因素。
Nat Rev Clin Oncol. 2022 Jul;19(7):441-457. doi: 10.1038/s41571-022-00619-z. Epub 2022 Apr 1.
5
Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses.免疫细胞图谱揭示胆管癌的不同肿瘤微环境和相关预后。
J Hematol Oncol. 2022 Mar 28;15(1):37. doi: 10.1186/s13045-022-01253-z.
6
Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy.雷莫芦单抗治疗吉西他滨为基础化疗后进展的晚期胆道癌的 II 期研究。
Clin Cancer Res. 2022 Jun 1;28(11):2229-2236. doi: 10.1158/1078-0432.CCR-21-3548.
7
Co-deficiency of B7-H3 and B7-H4 identifies high CD8 + T cell infiltration and better prognosis in pancreatic cancer.B7-H3 和 B7-H4 共缺失可鉴定出胰腺癌中高浸润的 CD8+T 细胞和更好的预后。
BMC Cancer. 2022 Feb 26;22(1):211. doi: 10.1186/s12885-022-09294-w.
8
First-Line Immunotherapy for Non-Small-Cell Lung Cancer.非小细胞肺癌的一线免疫治疗。
J Clin Oncol. 2022 Feb 20;40(6):586-597. doi: 10.1200/JCO.21.01497. Epub 2022 Jan 5.
9
Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma.蛋白质基因组学特征鉴定出肝内胆管癌的临床相关亚组。
Cancer Cell. 2022 Jan 10;40(1):70-87.e15. doi: 10.1016/j.ccell.2021.12.006. Epub 2021 Dec 30.
10
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.IMbrave150研究的更新疗效和安全性数据:阿替利珠单抗联合贝伐珠单抗对比索拉非尼治疗不可切除肝细胞癌。
J Hepatol. 2022 Apr;76(4):862-873. doi: 10.1016/j.jhep.2021.11.030. Epub 2021 Dec 11.